INTELLIGENT BIO SOLUTIONS INC.
Close on Oct 19, 2026
- Market cap
- $3.83M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2026 Ended Jun 30, 2026 | Aug 19, 2026 | Before market open | – | – | – |
| Q3 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | $1.06M | $-1.80 | – |
| Q2 FY2026 Ended Dec 31, 2025 | Feb 12, 2026 | Before market open | $896.77K | $-2.82 | – |
| Q1 FY2026 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | $1.11M | $-0.35 | – |
| Q4 FY2025 Ended Jun 30, 2025 | Aug 15, 2025 | After market close | $843.88K | – | – |
| Q3 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | $728.87K | – | – |
| Q2 FY2025 Ended Dec 31, 2024 | Feb 13, 2025 | After market close | $610.00K | $-0.50 | – |
| Q1 FY2025 Ended Sep 30, 2024 | Oct 29, 2024 | After market close | – | – | – |
| Q4 FY2024 Ended Jun 30, 2024 | Sep 19, 2024 | After market close | – | – | – |
| Q3 FY2024 Ended Mar 31, 2024 | Apr 18, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Dec 31, 2023 | Feb 9, 2024 | After market close | – | – | – |
Press releases
Announcements Intelligent Bio Solutions filed with the SEC
EX-99.1 to Form 8-K
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Submits FDA 510(k) Package for Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bio Solutions Announces Private Placement of up to $15 Million to a Single Existing Institutional Investor Priced At-the-Market Under
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge
Results of operations · EX-99.1 to Form 8-K
Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission
Regulation FD disclosure · EX-99.1 to Form 8-K
Interference Study Examining the Impact of Everyday Substances on Intelligent Fingerprinting System
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Achieves Key Milestone Ahead of Planned FDA 510(k) Submission, Advancing Toward Planned U.S. Market Entry
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Initiates Clinical Study Supporting FDA Clearance and Planned U.S. Market Entry
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year
Results of operations · EX-99.1 to Form 8-K
Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million
Results of operations · EX-99.1 to Form 8-K
Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S.
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Announces $10.0 Million Private Placement Priced
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Bio Solutions Announces New Manufacturing Partnership to Strengthen Global Production Capability and Increase Margins
Regulation FD disclosure · EX-99.1 to Form 8-K
Intelligent Bio Solutions Inc. Announces Reverse
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth
Results of operations · EX-99.1 to Form 8-K
Bio Solutions Expects to Report Record Fiscal First Quarter 2026 Revenue of Over $1 Million, an Increase of Approximately 32% Sequentially
Results of operations · EX-99.1 to Form 8-K
Bio Solutions Secures 33 New Customer Accounts in the Fiscal 2026 First Quarter, Showing Strong Year-Over-Year Growth and Increasing
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Advances Preparations and Provides Updated Timeline for Anticipated FDA 510(k) Submission and Clearance
Regulation FD disclosure · EX-99.1 to Form 8-K
Intelligent Bio Solutions Provides Update on
Other events · EX-99.1 to Form 8-K
Bio Solutions Reports Fiscal 2025 Fourth Quarter and Full Year Results, Highlighting Progress on Planned U.S. Market Expansion, Revenue
Results of operations · EX-99.1 to Form 8-K
Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational
Results of operations · EX-99.1 to Form 8-K
Bio Solutions Strengthens FDA 510(k) Package with New Cybersecurity and Performance Data Ahead of Planned U.S. Market Launch
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bio Solutions Inc. Enters Into Agreements to Raise $3.8 Million in Gross Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Bio Solutions to Strengthen FDA 510(k) Submission with New Positive Data Demonstrating Ultra-Precise Fingerprint Sweat Detection and
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Accelerates Global Growth with SmarTest® Patch Agreement, Reinforces U.S. Expansion Path as FDA Approval Remains a
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Adds Next-Gen Wearable for Extended Drug Detection to Product Offering, Strengthening Leadership in Non-Invasive Testing
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions Announces Fiscal Q3 2025 Financial Results and Key Operational Achievements
Results of operations · Executive or director change · Shareholder vote results · EX-99.1 to Form 8-K
Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio Solutions’ FDA Clearance Process Remains on Track for 2025 U.S. Launch
Regulation FD disclosure · EX-99.1 to Form 8-K